Importance Irritable bowel syndrome (IBS) affects 7% to 21% of the general population. It is
a chronic condition that can substantially reduce quality of life and work productivity …

The irritable bowel syndrome (IBS) is part of the larger group of functional gastrointestinal
(GI) disorders that, despite differences in location and symptom patterns, share common …

Functional bowel disorders are highly prevalent disorders found worldwide. These disorders
have the potential to affect all members of society, regardless of age, sex, race, creed, color …

The Rome IV Diagnostic Questionnaires were developed to screen for functional
gastrointestinal disorders, serve as inclusion criteria in clinical trials, and support …

Background Placebo treatment can significantly influence subjective symptoms. However, it
is widely believed that response to placebo requires concealment or deception. We tested …

The Rome criteria, which define disorders of gut-brain interaction (DGBIs), are extensively
applied in epidemiologic research, pathophysiologic studies, treatment trials, and clinical …

Objective To investigate whether placebo effects can experimentally be separated into the
response to three components—assessment and observation, a therapeutic ritual (placebo …

Background: IBS affects 5–11% of the population of most countries. Prevalence peaks in the
third and fourth decades, with a female predominance. Aim: To provide a guide for the …

Irritable bowel syndrome (IBS) is a common functional bowel disorder characterised by
symptoms of recurrent abdominal pain associated with a change in bowel habit. This …

The recent introduction of covert administration of treatment to biomedical research has
produced some interesting results, with many clinical and ethical implications. Concealed …